Finance

Lists
MRCK34:BVMF
Merck BDR
R$81.45
-0.39%
(-0.32) 1D
Aug 7, 4:56:00 PM GMT-3  ·   BRL
All symbols
SymbolPriceChange% Change
Generating top insights for MRCK34...
Open
R$81.77
High
R$81.84
Low
R$80.89
Mkt. cap
317.57B
Avg. vol.
0.00
Volume
84.00
52-wk high
R$86.41
52-wk low
R$51.06
Shares outstanding
2.47B
No. of employees
74K
Open
R$81.77
High
R$81.84
Low
R$80.89
Mkt. cap
317.57B
Avg. vol.
0.00
Volume
84.00
52-wk high
R$86.41
52-wk low
R$51.06
Shares outstanding
2.47B
No. of employees
74K
News stories
From sources across the web
Profile
Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada. The company is ranked fifth on the list of largest biomedical companies by revenue. The company's revenues are primarily from cancer treatments, vaccines, and animal health products. In 2024, 46% of the company's revenue, or $29.5 billion, came from sales of Keytruda, a PD-1 inhibitor used to treat various types of cancers, and 13% of the company's revenue, or $8.6 billion, came from sales of Gardasil, an HPV vaccine. In addition, 9% of the company's revenue, or $5.8 billion, came from the sales of animal health products. The company is ranked 65th on the Fortune 500 and 76th on the Forbes Global 2000. In 1891, Merck & Co. was established as the American affiliate of the Merck Group, founded by the Merck family, and the companies are still in trademark disputes in several countries over the right to use the name "Merck". Wikipedia
About Merck BDR
CEORobert M Davis
Employees74K
FoundedJan 1, 1891
Headquarters-
SectorPharmaceutical industry
Websitemerck.com
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
17.28B
16.40B
16.29B
16.61B
Cost of goods sold
3.74B
4.30B
3.88B
4.21B
Cost of revenue
3.74B
4.30B
3.88B
4.21B
Research and development expenses
4.00B
4.00B
3.56B
9.74B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.48B
2.73B
2.57B
2.89B
Operating expense
6.48B
6.73B
6.12B
12.62B
Total operating expenses
10.23B
11.02B
10.00B
16.83B
Operating income
7.05B
5.38B
6.29B
-227.00M
Other non operating income
-
41.00M
42.00M
-290.00M
EBT including unusual items
6.74B
3.42B
-3.53B
-683.00M
EBT excluding unusual items
6.76B
4.98B
5.85B
-517.00M
Income tax expense
958.00M
458.00M
709.00M
654.00M
Effective tax rate
14.20%
13.39%
-20.06%
-95.75%
Other operating expenses
-
-
-
-
Net income
5.78B
2.96B
-4.24B
-1.34B
Net profit margin
33.49%
18.07%
-26.03%
-8.04%
Earnings per share
2.58
2.04
-1.28
-0.13
Interest and investment income
96.00M
69.00M
35.00M
-
Interest expense
-327.00M
-411.00M
-479.00M
-
Net interest expenses
-231.00M
-342.00M
-444.00M
-
Depreciation and amortization charges
-
-
-
-
EBITDA
8.15B
6.79B
7.69B
1.18B
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps